Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

A role for the androgen receptor in the treatment of male breast cancer.

Publication ,  Journal Article
Zhu, J; Davis, CT; Silberman, S; Spector, N; Zhang, T
Published in: Crit Rev Oncol Hematol
February 2016

Male breast cancer (BC) is relatively rare, making up less than 1% of all breast cancer cases in the United States. Treatment guidelines for male BC are derived from studies on the treatment of female BC, and are based molecular and clinical characteristics, such as hormone receptor positivity. For female estrogen receptor positive (ER+) breast cancers, the standard of care includes three classes of endocrine therapies: selective estrogen receptor modulators, aromatase inhibitors, and pure anti-estrogens. In contrast to female ER+ breast cancers, there is less known about the optimal treatment for male ER+ BC. Furthermore, in contrast to ER, less is known about the role of the androgen receptor (AR) in male and female BC. We report here the treatment of a 28-year-old man with metastatic AR+, ER+ breast cancer otherwise refractory to chemotherapy, who has had a durable clinical response to hormonal suppression with the combination of aromatase inhibition (Letrozole) in conjunction with a GnRH agonist (Leuprolide).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Crit Rev Oncol Hematol

DOI

EISSN

1879-0461

Publication Date

February 2016

Volume

98

Start / End Page

358 / 363

Location

Netherlands

Related Subject Headings

  • Receptors, Estrogen
  • Receptors, Androgen
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Breast Neoplasms, Male
  • Androgen Antagonists
  • Adult
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhu, J., Davis, C. T., Silberman, S., Spector, N., & Zhang, T. (2016). A role for the androgen receptor in the treatment of male breast cancer. Crit Rev Oncol Hematol, 98, 358–363. https://doi.org/10.1016/j.critrevonc.2015.11.013
Zhu, Jason, Carter T. Davis, Sandra Silberman, Neil Spector, and Tian Zhang. “A role for the androgen receptor in the treatment of male breast cancer.Crit Rev Oncol Hematol 98 (February 2016): 358–63. https://doi.org/10.1016/j.critrevonc.2015.11.013.
Zhu J, Davis CT, Silberman S, Spector N, Zhang T. A role for the androgen receptor in the treatment of male breast cancer. Crit Rev Oncol Hematol. 2016 Feb;98:358–63.
Zhu, Jason, et al. “A role for the androgen receptor in the treatment of male breast cancer.Crit Rev Oncol Hematol, vol. 98, Feb. 2016, pp. 358–63. Pubmed, doi:10.1016/j.critrevonc.2015.11.013.
Zhu J, Davis CT, Silberman S, Spector N, Zhang T. A role for the androgen receptor in the treatment of male breast cancer. Crit Rev Oncol Hematol. 2016 Feb;98:358–363.
Journal cover image

Published In

Crit Rev Oncol Hematol

DOI

EISSN

1879-0461

Publication Date

February 2016

Volume

98

Start / End Page

358 / 363

Location

Netherlands

Related Subject Headings

  • Receptors, Estrogen
  • Receptors, Androgen
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Breast Neoplasms, Male
  • Androgen Antagonists
  • Adult
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology